Vice Chair: Jun J. Yang, PhD

Division of Pharmaceutical Sciences

The Division of Pharmaceutical Sciences operates with a mission to improve efficacy and reduce toxicity of drug therapy. Fundamental science has always been represented in our research portfolio, with faculty exploring mechanisms of drug transport, drug metabolism, and the genetic basis for interindividual differences in response to drug therapy. We continue to build on our groundbreaking efforts in pharmacogenomics and lead the world in discovery and clinical application. Our faculty are dissecting coding and non-coding regions of the genome to drive improvements in drug therapy, developing more accurate models of pediatric cancers for preclinical evaluation, and elucidating the basis of resistance to anticancer and anti-infective agents. The Division integrates expertise in pharmacokinetics, pharmacodynamics, and pharmacogenomics with state-of-the-art technologies to establish new knowledge and improve patient care.

Our Research Focus AreasĀ 

William E. Evans, PharmD [Emeritus]: pharmacogenomics of antileukemic agents

Mary V. Relling, PharmD: pharmacogenomics and leukemia therapy

P. David Rogers, PharmD, PhD, FCCP: molecular and genetic basis of antifungal pharmacotherapy

Jeffrey M. Rybak, PharmD, PhD: development, enhancement, and preservation of antifungal pharmacotherapy

Daniel Savic, PhD: Pharmacogenomics and cis-regulatory architecture of pediatric leukemia

Erin G. Schuetz, PhD: Pharmacogenetics and regulation of drug detoxification genes

John D. Schuetz, PhD: ABC transporters and mitochondrial biology

Clinton F. Stewart, PharmD: Pharmacokinetics and anticancer drug development

Jun J. Yang, PhD: Pharmacogenomics of anticancer agents and drug resistance

Liqin Zhu, PhD: Stem cells in normal and malignant development

Affiliated Programs